| Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286-295, 2019 | 571 | 2019 |
| Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ... Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022 | 518 | 2022 |
| Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ... Jama 318 (9), 825-835, 2017 | 506 | 2017 |
| Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers MY Teo, K Seier, I Ostrovnaya, AM Regazzi, BE Kania, MM Moran, ... Journal of Clinical Oncology 36 (17), 1685-1694, 2018 | 483 | 2018 |
| Epidemiology of renal cell carcinoma: 2022 update L Bukavina, K Bensalah, F Bray, M Carlo, B Challacombe, JA Karam, ... European urology 82 (5), 529-542, 2022 | 414 | 2022 |
| Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy C Krishna, RG DiNatale, F Kuo, RM Srivastava, L Vuong, D Chowell, ... Cancer cell 39 (5), 662-677. e6, 2021 | 269 | 2021 |
| NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, S Boyle, MI Carlo, B Manley, N Agarwal, A Alva, ... Journal of the National Comprehensive Cancer Network 18 (9), 1160-1170, 2020 | 230 | 2020 |
| Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma MI Carlo, S Mukherjee, D Mandelker, J Vijai, Y Kemel, L Zhang, ... JAMA oncology 4 (9), 1228-1235, 2018 | 174 | 2018 |
| BAP1 tumor predisposition syndrome R Pilarski, MI Carlo, C Cebulla, M Abdel-Rahman | 153 | 2022 |
| Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates CH Lee, MH Voss, MI Carlo, YB Chen, M Zucker, A Knezevic, ... Journal of Clinical Oncology 40 (21), 2333-2341, 2022 | 138 | 2022 |
| Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors EM Fiala, G Jayakumaran, A Mauguen, JA Kennedy, N Bouvier, Y Kemel, ... Nature cancer 2 (3), 357-365, 2021 | 126 | 2021 |
| Familial kidney cancer: implications of new syndromes and molecular insights MI Carlo, AA Hakimi, GD Stewart, G Bratslavsky, J Brugarolas, YB Chen, ... European urology 76 (6), 754-764, 2019 | 120 | 2019 |
| Therapeutic implications of germline testing in patients with advanced cancers ZK Stadler, A Maio, D Chakravarty, Y Kemel, M Sheehan, E Salo-Mullen, ... Journal of Clinical Oncology 39 (24), 2698-2709, 2021 | 114 | 2021 |
| Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma MI Carlo, MH Voss, RJ Motzer Nature Reviews Urology 13 (7), 420-431, 2016 | 109 | 2016 |
| A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma MI Carlo, AM Molina, Y Lakhman, S Patil, K Woo, J DeLuca, CH Lee, ... The oncologist 21 (7), 787-788d, 2016 | 108 | 2016 |
| Cancer susceptibility mutations in patients with urothelial malignancies MI Carlo, V Ravichandran, P Srinavasan, C Bandlamudi, Y Kemel, ... Journal of Clinical Oncology 38 (5), 406-414, 2020 | 95 | 2020 |
| Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders A Boilève, MI Carlo, P Barthelemy, S Oudard, D Borchiellini, MH Voss, ... Journal for immunotherapy of cancer 6, 1-10, 2018 | 80 | 2018 |
| Inherited TP53 variants and risk of prostate cancer KN Maxwell, HH Cheng, J Powers, R Gulati, EM Ledet, C Morrison, A Le, ... European urology 81 (3), 243-250, 2022 | 73 | 2022 |
| The context-specific role of germline pathogenicity in tumorigenesis P Srinivasan, C Bandlamudi, P Jonsson, Y Kemel, SS Chavan, ... Nature genetics 53 (11), 1577-1585, 2021 | 73 | 2021 |
| Comprehensive molecular characterization and response to therapy in fumarate hydratase–deficient renal cell carcinoma JP Gleeson, I Nikolovski, R Dinatale, M Zucker, A Knezevic, S Patil, Y Ged, ... Clinical Cancer Research 27 (10), 2910-2919, 2021 | 67 | 2021 |
